Abstract
Left ventricular assist device (LVAD) therapy improves survival in inotrope-dependent heart failure patients (pts) and can make pts with pulmonary hypertension and/or end-organ dysfunction eligible for heart transplantation (HTx), but device-related complications are frequent. In Italy donor hearts supply is much lower than demand, and stable LVAD pts have no priority for organ allocation. Thus, HTx candidates may refuse LVAD and ask for less invasive therapy when ambulatory, and prefer short-term support when deteriorating, despite the risk of death while awaiting or after emergency HTx. We report on pts treated with LVAD or repeated Levosimendan as a bridge to HTx or to candidacy at a single Italian center.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
